| Identification | Back Directory | [Name]
UVAOL | [CAS]
545-46-0 | [Synonyms]
UVAOL
UVAOL(SH)
UVAOL hplc
UVAOL WITH HPLC
12-URSEN-3B,28-DIOL
URS-12-ENE-3,28-DIOL
12-URSEN-3BETA, 28 DIOL
urs-12-ene-3beta,28-diol
3B,28-DIHYDROXY-URSA-12-EN
Uvaol,Urs-12-ene-3,28-diol
3BETA,28-DIHYDROXY-URSA-12-EN
(3S,4aR,6aR,6bS,8aS,11R,12S,12aS,14aR,14bR)-8a-(hydroxymethyl)-4,4,6a,6b,11,12,14b-heptamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picen-3-ol | [EINECS(EC#)]
208-888-3 | [Molecular Formula]
C30H50O2 | [MDL Number]
MFCD00009620 | [MOL File]
545-46-0.mol | [Molecular Weight]
442.72 |
| Chemical Properties | Back Directory | [Melting point ]
223-225 °C(lit.)
| [Boiling point ]
523.7±50.0 °C(Predicted) | [density ]
1.05±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), Ethyl Acetate (Slightly) | [form ]
Solid | [pka]
15.09±0.10(Predicted) | [color ]
White to Off-White | [LogP]
9.130 (est) | [CAS DataBase Reference]
545-46-0 |
| Hazard Information | Back Directory | [Definition]
ChEBI: A natural product found in Rhododendron ferrugineum. | [Uses]
Uvaol can attenuate pleuritis and eosinophillic inflammation in mice that is induced by ovalbumin. It is an essential reagent in the synthesis of aminopropoxytriterpenoids that have anticancer activity. | [Biological Activity]
Uvaolexerts pharmacological properties such as antioxidantanticanceranti-inflammatoryand wound healing. It also displays vasodilatorhepatoprotectiveand antimicrobial effects. Uvaol has inhibitory effects on nitric oxide (NO) release. | [in vivo]
Uvaol (100-500 μmol/kg; orally administered; 60 min before antigen challenge) can reduce pleural eosinophilic inflammation and IL-5 concentration in a murine pleurisy model induced by ovalbumin[1]. | Animal Model: | Male Swiss mice (weighing 25-30 g) with subcutaneous (s.c.) injection on days 0 and 7 with 0.2 mL of a solution containing 50 μg of Ovalbumins (OVA) (HY-W250978) adsorbed to 5 mg of aluminum hydroxide[1]. | | Dosage: | 100 μmol/kg, 200 μmol/kg, 500 μmol/kg (2% DMSO in sterile saline) | | Administration: | Oral administration; 60 min before antigen challenge | | Result: | Caused a significant decrease in total leukocyte accumulation.
Induced a significant reduction in the levels of this cytokine. |
|
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
|